The Claim
PCSK9 inhibitors are effective in reducing low-density lipoprotein cholesterol (LDL-C) levels when used as an addition to existing lipid-lowering therapies or as a substitute for other active lipid-lowering treatments.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
PCSK9 inhibitors can help lower bad cholesterol, either when added to other treatments or used instead of them.
See the scientific wording
PCSK9 inhibitors demonstrate efficacy in lowering LDL-cholesterol both as add-on therapy to existing treatments and as an alternative to other active lipid-lowering regimens.
What the research says
1 studyStudy: Ldl-cholesterol reduction with PCSK9 inhibitors: A meta-analysis of randomised controlled trials.
The study shows that PCSK9 inhibitors really do lower bad cholesterol, whether added to other treatments or used instead of them.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.